IgG Glycome in Colorectal Cancer
Authors:
Open Access
- 14 June 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (12) , 3078-3086
Abstract
Purpose: Alternative glycosylation has significant structural and functional consequences on IgG and consequently also on cancer immunosurveillance. Because of technological limitations, the effects of highly heritable individual variations and the differences in the dynamics of changes in IgG glycosylation on colorectal cancer were never investigated before.Experimental Design: Using recently developed high-throughput UPLC technology for IgG glycosylation analysis, we analyzed IgG glycome composition in 760 patients with colorectal cancer and 538 matching controls. Effects of surgery were evaluated in 28 patients sampled before and three times after surgery. A predictive model was built using regularized logistic regression and evaluated using a 10-cross validation procedure. Furthermore, IgG glycome composition was analyzed in 39 plasma samples collected before initial diagnosis of colorectal cancer.Results: We have found that colorectal cancer associates with decrease in IgG galactosylation, IgG sialylation and increase in core-fucosylation of neutral glycans with concurrent decrease of core-fucosylation of sialylated glycans. Although a model based on age and sex did not show discriminative power (AUC = 0.499), the addition of glycan variables into the model considerably increased the discriminative power of the model (AUC = 0.755). However, none of these differences were significant in the small set of samples collected before the initial diagnosis.Conclusions: Considering the functional relevance of IgG glycosylation for both tumor immunosurveillance and clinical efficacy of therapy with mAbs, individual variation in IgG glycosylation may turn out to be important for prediction of disease course or the choice of therapy, thus warranting further, more detailed studies of IgG glycosylation in colorectal cancer. Clin Cancer Res; 22(12); 3078–86. ©2016 AACR.Keywords
All Related Versions
Funding Information
- Cancer Research UK, EU HighGlycans FP7 (C348/A12076)
- University of Edinburgh
- European Commission GlycoBioM (no. 259869)
- IBD-BIOM (305479)
- HighGlycan (278535)
- MIMOmics (305280)
- HTP-GlycoMet (324400)
- IntegraLife (315997)
- GlyCoCan (676412)
This publication has 45 references indexed in Scilit:
- Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological CancersPLOS Genetics, 2013
- High Throughput Isolation and Glycosylation Analysis of IgG–Variability and Heritability of the IgG Glycome in Three Isolated Human PopulationsMolecular & Cellular Proteomics, 2011
- Clinical Significance of Osteoprotegerin Expression in Human Colorectal CancerClinical Cancer Research, 2011
- Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritisArthritis & Rheumatism, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Thirty-five-year trends in cardiovascular risk factors in FinlandInternational Journal of Epidemiology, 2009
- Transcriptome Profile of Human Colorectal AdenomasMolecular Cancer Research, 2007
- Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIaClinical Cancer Research, 2006
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002
- Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein.Gut, 1990